EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Eating less salt can prevent tens of thousands of heart attacks and strokes Lowering the amount of salt in processed foods or choosing low-salt alternatives can lead to substantial health benefits when it comes to cardiovascular disease.
Large differences in childhood obesity in Europe The percentage of overweight (including obesity) among 6-9-year-old children differs between European countries, ranging from 18 to 57%. Percentages are highest in southern European countries.
The number of STI tests keeps increasing The number of clients tested for sexually transmitted infections (STIs) at Dutch STI clinics has increased since 2004.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
RIVM provides overview of the possible risks of bisphenol A RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.
Is screening for sexually transmitted infections as part of HIV care cost-effective in the Netherlands? Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.
Regional differences in testing rates underestimate incidence of LGV epidemic Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.